AngioDynamics closes $55M Vortex buy; Medical device tax repeal could get through Senate;

 @FierceMedDev: JNJ pulled in $7.1 billion from medical devices and diagnostics in Q3, a 12.5% jump. More | Follow @FierceMedDev

 @MarkHFierce: Patients in India thrived with used ICD implants. Can this be done on a broader scale? More | Follow @MarkHFierce

 @DamianFierce: Medtronic is buying a $66.2M stake in China's LifeTech Scientific, makers of cardiovascular devices. More | Follow @DamianFierce

> AngioDynamics ($ANGO) has closed its purchase of Vortex Medical, a deal worth $55 million over five years. News

> Devicemaker ICU Medical posted a third-quarter profit of $12.2 million, a 31% jump over the previous year. Article

> Hologic ($HOLX) picked up FDA approval for its Aptima HPV diagnostic assay, designed for the company's Tigris test platform. More

> HemoSonics is partnering with Cambridge Consultants to finalize the development of a new diagnostic instrument for blood clotting. Item

> A Pennsylvania court dismissed a few of the claims against Stryker ($SYK) over its CerviCore implant, but the company still faces negligence charges. Story

> Thermo Fisher Scientific ($TMO) has launched the MYCEL Imager, an imaging tool designed to capture and analyze protein and nucleic acid gels and Western blots. Release

> There's a chance the effort to repeal the 2.3% excise tax on medical devices could clear the Senate, but it's unlikely to have enough support to overturn the resulting presidential veto. Analysis

Biotech News

 @FierceBiotech: New special report on 10 promising therapeutic vaccines in 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Genzyme, likely to get some tough safety questions on Kynamro at this week's FDA panel. More | Follow @JohnCFierce

 @RyanMFierce: Piramal is poised to be a big consolidator in pharma services/manufacturing, but apparently only at the right price. More | Follow @RyanMFierce

> FDA frets over safety of Genzyme's rival drug for rare cholesterol disease. Article

> Bullish Roche talks targeted takeovers, showcases T-DM1's prospects. Story

> ArQule, Threshold get a bounce out of PhIII SPA pacts with FDA. Report

Pharma News

@FiercePharma: Other compounded drugs may be tied into meningitis outbreak, FDA says. Another NECC steroid + NECC heart drug. More | Follow @FiercePharma

> J&J credits Remicade, Zytiga for 7% hike in Q3 drug sales. Story

> Roche sales hike sums up pharma hopes for cancer, emerging markets. Article

> India kicks branded generics to the curb. Report

Biotech Research News

> NIH funds Advanced Cancer Therapeutics' preclinical brain cancer drug work. Report

> Scientists flee $3B Texas cancer research fund. Item

> Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer. Article

> Alzheimer's drug builds new brain cell connections in rats. News

> Scientists build neural-like stem cells from mouse muscle tissue. Story

Pharma Manufacturing News

> GSK cancels plans to close Stiefel plant in Ireland. Story

> Cinven continues generics deal spree with Amdipharm buy. Article

> Teva Pharma opens $110M plant in Hungary. News

> Analysis: Compounding groups fought FDA oversight before NECC disaster. Report


Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.